Oncologists are operating in a whole new world as healthcare transitions to value-based care.
By now all oncologists know that the implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) is shifting physician reimbursement from a volume- to a value-based model. To succeed with MACRA, practices must become familiar with how this will affect them and get ready to incorporate the new measures to ensure they get the best level of reimbursement under this program.
Cancer drug costs are escalating at an even faster rate, at least in part because of accelerated new approvals by the FDA and higher drug unit costs.
The National Organization of Rheumatology Managers (NORM) hosted a Centers for Medicare & Medicaid (CMS) webinar on the Quality Payment Program—which is based on the Medicare Access and CHIP Reauthorization Act (MACRA)—for NORM members.
Results 1 - 4 of 4